Press Releases

December 13, 2022 at 8:30 AM EST

Summary Toggle Arcturus Appoints John Markels, Ph.D. to its Board of Directors

Dr. Markels , accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company’s vaccine franchise SAN DIEGO --(BUSINESS WIRE)--Dec. 13, 2022-- Arcturus Therapeutics Holdings Inc.

PDF Version
December 12, 2022 at 8:30 AM EST

Summary Toggle CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens KING OF PRUSSIA, Pa. , Dec. 12, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announced

PDF Version
November 9, 2022 at 4:01 PM EST

Summary Toggle Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress

Entered into global partnership with CSL to develop and commercialize self-amplifying mRNA vaccines targeting COVID-19, influenza, additional pathogens, and pandemic preparedness with $200 million upfront and up to $4.3 billion in potential development and commercial milestones BARDA award

PDF Version
November 7, 2022 at 5:00 PM EST

Summary Toggle Arcturus Therapeutics to Present at the Following Investor Conferences in November

SAN DIEGO --(BUSINESS WIRE)--Nov. 7, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

PDF Version
November 1, 2022 at 6:05 PM EDT

Summary Toggle Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Arcturus to receive upfront payment of $200 million and more than $4 billion in potential development and commercial milestones 40% profit sharing for COVID-19 vaccines, up to double digit royalties for influenza, pandemic preparedness and three additional respiratory infectious disease vaccines

PDF Version
October 26, 2022 at 4:30 PM EDT

Summary Toggle Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022

SAN DIEGO --(BUSINESS WIRE)--Oct. 26, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and

PDF Version
September 27, 2022 at 6:00 PM EDT

Summary Toggle Arcturus Therapeutics to Attend the Following Investor Conferences

SAN DIEGO --(BUSINESS WIRE)--Sep. 27, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare

PDF Version
September 1, 2022 at 4:00 PM EDT

Summary Toggle Arcturus Therapeutics to Attend the Following Investor Conferences

SAN DIEGO --(BUSINESS WIRE)--Sep. 1, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare

PDF Version
August 31, 2022 at 4:00 PM EDT

Summary Toggle Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response

Arcturus will expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform with the support of the Biomedical Advanced Research and Development Authority $63.2 Million base award to fund development from

PDF Version
August 18, 2022 at 8:00 AM EDT

Summary Toggle Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

New clinical data demonstrate high and sustained geometric mean fold rises (GMFR) in neutralizing antibodies against all evaluated Omicron variants Six months after booster dose of ARCT-154: BA.1: GMFR = 22 to 52; Titer = 674 to 1524 BA.2: GMFR = 25 to 55; Titer = 777 to 1713 BA.5: GMFR = 9 to

PDF Version